News

OverviewTransthyretin cardiac amyloidosis causes debilitating heart failure in older adults. The proposed research will develop a personalized exercise training…

Position: The Development Manager for the Amyloidosis Research Consortium (ARC) will be responsible for managing the full lifecycle of donor data, from initial…

Differences versus placebo seen within 30 days, sustained to 30 monthsNew analyses suggest Attruby (acoramidis) may reduce the risk of outpatient worsening heart…

73% of Respondents Had Never Heard of ATTR-CM, a Serious Heart Condition Where Women Face Later Diagnosis, Lower Treatment Rates, And Worse Outcomes CHICAGO,…

Cardiac amyloidosis on nuclear imaging of the heart using 11C-PiB PET/CT. Image courtesy of RSNACardiac amyloidosis research is a growing area in cardiology thanks…

OverviewThe study is conducted in participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a heart disease that occurs in people with the disease ATTR…

Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as a significant yet frequently overlooked etiology of heart failure, particularly within the elderly…

At AstraZeneca, we turn ideas into life-changing medicines. Working here means being entrepreneurial, thinking big, and collaborating to make the impossible a…

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized yet frequently underdiagnosed cause of heart failure, particularly among older…

AbstractCardiac amyloidosis (CA) is an infiltrative myocardiopathy caused by extracellular deposits of misfolded proteins, with evolution to heart failure (HF) and…